The haemodynamic profile of cisatracurium

Current Opinion in Anaesthesiology

Volumn 9, Issue SUPPL. 1, 1996, Pages

  Savarese, John J ^a   Viby Møgensen, Jørgen ^b   Reich, David ^c   Van Aken, Hugo ^d  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; HISTAMINE; NEUROMUSCULAR BLOCKING AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CONFERENCE PAPER; DRUG CLEARANCE; DRUG SAFETY; HEMODYNAMICS; HISTAMINE RELEASE; HUMAN; PRIORITY JOURNAL; STEREOISOMERISM;

EID: 0029885560     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-199604001-00008     Document Type: Conference Paper

References (14)

1. Basta SJ, Savarese JJ, Ali HH, Moss J, Gionfriddo M: Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine. Br J Anaesth 1983, 55 (suppl 1):105S-106S.
2. Watkins J: Histamine release and atracurium. Br J Anaesth 1986, 58 (suppl 1):19S-22S.
3. Basta SJ: Modulation of histamine release by neuromuscular-blocking drugs. Curr Opin Anaesth 1993, 5:572-576.
4. Agoston S, Vandenbrom RHG, Wierda JMKH: Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet 1992, 22:94-115.
5. Wastila WB, Maehr RB, LaMunion GL, Belmont MR, Savarese JJ: Preclinical pharmacology of cisatracurium besylate. Curr Opin Anaesthesiol 1996, 9 (suppl 1):S2-S8.
6. Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ: The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995, 82:1131-1138.
7. Lepage JY, Malinovsky JM, Cozian A, Pinaud M: Pharmacodynamics and histamine releasing potency of high doses of 51W89 [abstract]. Anesthesiology 1994, 81:A1077.
8. Reich DL, Konstadt SN, Stanley TE, DePerio M, Chuey C, Schwartzbach C: A two-center study of the cardiovascular effects of 51W89 in patients with coronary artery disease. Anesth Analg 1995, 81:1010-1041.
9. Meretoja OA, Taivainen T, Wirtavuori K: Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia. Br J Anaesth 1995, 74:6-11.
10. Meretoja OA: Pharmacodynamics and safety of cisatracurium in children aged 2-12 years undergoing anaesthesia. Curr Opin Anaesthesiol 1996, 9 (suppl 1):S27-S31.
11. Wright PMC, Ornstein E: Pharmacokinetics, pharmacodynamics and safety of cisatracurium in elderly partients. Curr Opin Anaesthesiol 1996, 9 (suppl 1):S32-S35.
12. Barnes PK, DeRenzy-Martin N, Thomas VJE, Watkins J: Plasma histamine levels following atracurium. Anesthesia 1986, 41:821-824.
13. Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo MA, Cloutier G, Lineberry CG, Cato AE: Clinical pharmacology of atracurium besylate (BW 33A): a new nondepolarizing muscle relaxant. Anesth Analg 1982, 61:723-729.
14. Scott RPF, Savarese JJ, Basta SJ, Embree PB, Ali HH, Sunder N, Hoaglin DC: Clinical pharmacology of atracurium given in high dose. Br J Anaesth 1986, 58:834-838.